A once-daily dose of tadalafil for erectile dysfunction: Compliance and efficacy

Drug Design, Development and Therapy

Volumn 4, Issue , 2010, Pages 159-171

  Washington, Samuel L ^a   Shindel, Alan W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Daily dosing; On demand therapy; PDE5 inhibitor; Side effects

Indexed keywords

ANDROGEN; DOXAZOSIN; PHOSPHODIESTERASE V INHIBITOR; PHOSPHODIESTERASE VI; PLACEBO; SILDENAFIL; TADALAFIL; TAMSULOSIN; CARBOLINE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR;

ABDOMINAL PAIN; ANDROGEN BLOOD LEVEL; ANGINA PECTORIS; BACKACHE; BETA RHYTHM; CARDIOVASCULAR SYMPTOM; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PREFERENCE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAM; ERECTILE DYSFUNCTION; GRAPEFRUIT JUICE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART RATE; HUMAN; HYPERTENSION; LABORATORY TEST; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MYALGIA; NONHUMAN; NOSE CONGESTION; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SEXUAL FUNCTION; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; SIDE EFFECT; SPERMATOZOON DENSITY; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; VISUAL DISORDER; ANIMAL; DRUG ADMINISTRATION; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; MALE; PATHOPHYSIOLOGY; UNITED STATES;

ANIMALS; CARBOLINES; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; ERECTILE DYSFUNCTION; HUMANS; MALE; MEDICATION ADHERENCE; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79952060145     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. NIH Panel on Impotence. NIH Consensus Conference: Impotence. JAMA. 1993;270:83-90.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.
3. Feldman HA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prev Med. 2000;30(4):328-338.
4. Miner MM, Kuritzky L. Erectile dysfunction: a sentinel marker for cardiovascular disease in primary care. Cleve Clin J Med. 2007; 74 Suppl 3:S30-S37.
5. Fisher WA, Eardley I, McCabe M, Sand M. Erectile dysfunction (ED) is a shared sexual concern of couples II: association of female partner characteristics with male partner ED treatment seeking and phosphodiesterase type 5 inhibitor utilization. J Sex Med. 2009;6(11):3111-3124.
6. Tsertsvadze A, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and metaanalysis. Ann Intern Med. 2009;151(9):650-661.
7. Carson CC. PDE5 inhibitors: are there differences? Can J Urol. 2006; 13(Suppl 1):34-39.
8. Ljunggren C, Hedelin H, Salomonsson K, Stroberg P. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J Sex Med. 2008;5:469-475.
9. Paick JS, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008;5:946-953.
10. Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. J Sex Med. 2009;6(9):2352-2364;quiz 2365-2366.
11. Coward RM, Carson CC. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag. 2008;4:1315-1330.
12. Forgue ST, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006;61:280-288.
13. Eardley I, Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract. 2002;56:300-304.
14. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol. 1998;159(5):1541-1547.
15. Porst H, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003;62(1):121-125; discussion 125-126.
16. Taylor J, Baldo OB, Storey A, Cartledge J, Eardley I. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int. 2009;103(10):1392-1395.
17. Vernet D, et al. Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J Sex Med. 2006;3:84-94; discussion 94-95.
18. Lin G, Xin ZC, Lue TF, Lin CS. Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism. J Urol. 2003;170:S15-S18; discussion S19.
19. Costa P, Grivel T, Gehchan N. Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives. Patient Prefer Adherence. 2009;3:105-111.
20. Wrishko R, Sorsaburu S, Wong D, Strawbridge A, McGill J. Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. J Sex Med. 2009;6:2039-2048.
21. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med. 2004;1:292-300.
22. Mirone V, et al. An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol. 2005;47:846-854; discussion 854.
23. Costa P, et al. Predictors of tadalafil efficacy in men with erectile dysfunction: the SURE study comparing two dosing regimens. J Sex Med. 2006;3:1050-1058.
24. Moncada I, et al. Sexual intercourse attempt patterns with two dosing regimens of tadalafil in men with erectile dysfunction: results from the SURE study in 14 European countries. J Sex Med. 2005;2:668-674.
25. Buvat J, et al. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled Use vs. On-Demand Regimen Evaluation (SURE) study in 14 European countries. J Sex Med. 2006;3:512-520.
26. Affuso F, Palmieri EA, Di Conza P, Guardasole V, Fazio S. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol. 2006;108:429-431.
27. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180:1228-1234.
28. Rosato E, et al. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis. J Biol Regul Homeost Agents. 2009;23:23-29.
29. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802-1813.
30. Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res. 2004;16 Suppl 1:S4-S7.
31. El-Sakka AI, Lin CS, Chui RM, Dahiya R, Lue TF. Effects of diabetes on nitric oxide synthase and growth factor genes and protein expression in an animal model. Int J Impot Res. 1999;11:123-132.
32. Miles CL, et al. Interventions for sexual dysfunction following treatments for cancer. Cochrane Database Syst Rev. 2007;CD005540.
33. Rosen RC, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822-830.
34. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology. 1999;54:346-351.
35. Shabsigh R, et al. Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success. Int J Impot Res. 2010;22(1):1-8.
36. Cappelleri JC, et al. Development and validation of the self-esteem and relationship (SEAR) questionnaire in erectile dysfunction. Int J Impot Res. 2004;16:30-38.
37. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol. 2001;65:1-52.
38. Cordell WH, et al. Retinal effects of 6 months of daily use of tadalafil or sildenafil. Arch Ophthalmol. 2009;127:367-373.
39. Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res. 2004;16(Suppl 1): S11-S14.
40. Rosen RC, et al. Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study. J Sex Med. 2004;1:193-200.
41. Francis SH, Morris GZ, Corbin JD. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function. Int J Impot Res. 2008;20:333-342.
42. Porst H, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006;50:351-359.
43. Donatucci CF, et al. Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option. Curr Med Res Opin. 2008;24:3383-3392.
44. Forgue ST, et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol. 2007;63:24-35.
45. Kloner RA, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol. 2003;42:1855-1860.
46. McMahon C. Comparison of efficacy, safety, and tolerability of ondemand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med. 2005;2:415-425; discussion 425-427.
47. Rajfer J, et al. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res. 2007;19:95-103.
48. Porst H, et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med. 2008;5:2160-2169.
49. Hatzichristou D, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med. 2008;25:138-146.
50. Porst H, et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol. 2009;56:727-735.
51. Conaglen HM, Conaglen JV. Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study. J Sex Med. 2008;5:1198-1207.
52. Rubio-Aurioles E, et al. Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. J Sex Med. 2009;6:1314-1323.
53. Seftel AD, et al. Improvements in confidence, sexual relationship and satisfaction measures: results of a randomized trial of tadalafil 5 mg taken once daily. Int J Impot Res. 2009;21:240-248.
54. Althof SE, et al. Impact of tadalafil once daily in men with erectile dysfunction-including a report of the partners' evaluation. Urology. 2010;75(6):1358-1363.
55. Hellstrom WJ, et al. An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20 mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. Eur Urol. 2008;53:1058-1065.
56. Beasley CM Jr, et al. The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. J Am Coll Cardiol. 2005;46:678-687.
57. Guillaume M, Lonsdale F, Darstein C, Jimenez MC, Mitchell MI. Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects. J Clin Pharmacol. 2007;47:1303-1310.
58. Kloner RA, et al. Cardiovascular safety update of tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol. 2006;97:1778-1784.
59. Okuyucu EE, et al. EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor. Neurol Res. 2009;31:313-315.
60. Demchenko IT, Ruehle A, Allen BW, Vann RD, Piantadosi CA. Phosphodiesterase-5 inhibitors oppose hyperoxic vasoconstriction and accelerate seizure development in rats exposed to hyperbaric oxygen. J Appl Physiol. 2009;106:1234-1242.
61. Maddox PT, Saunders J, Chandrasekhar SS. Sudden hearing loss from PDE-5 inhibitors: a possible cellular stress etiology. Laryngoscope. 2009;119:1586-1589.
62. Hong BN, Yi TH, Kim SY, Kang TH. High dosage sildenafil induces hearing impairment in mice. Biol Pharm Bull. 2008;31:1981-1984.
63. Okuyucu S, Guven OE, Akoglu E, Ucar E, Dagli S. Effect of phosphodiesterase-5 inhibitor on hearing. J Laryngol Otol. 2009;123:718-722.
64. Magheli A, Burnett AL. Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol. 2009;6:415-427.
65. Teloken P, Mesquita G, Montorsi F, Mulhall J. Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners. J Sex Med. 2009;6:2032-2038.
66. Montorsi F, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008;54:924-931.
67. Bannowsky A, Schulze H, van der Horst C, Hautmann S, Junemann KP. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int. 2008;101:1279-1283.
68. Padma-Nathan H, et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res. 2008;20:479-486.
69. Albersen M, Joniau S, Claes H, Van Poppel H. Preclinical evidence for the benefits of penile rehabilitation therapy following nerve-sparing radical prostatectomy. Adv Urol. 2008;594868.
70. Mulhall JP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol. 2008;18:613-620.
71. Walker DK, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999;29:297-310.
72. Vignozzi L, et al. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med. 2006;3:419-431.
73. Kovanecz I, et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int. 2008;101:203-210.
74. Aversa A, et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res. 2007;19:200-207.